The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease

Bibliography

• FELDMANN M, BRENNAN FM, MAINI RN: Role of cytoki-nes in rheumatoid arthritis. Ann. Rev. Immune]. (1996) 14:397–440.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, ELLIOTT MJ, WOODY JN et al.: Anti-tumor necrosis factor-a treatment of rheumatoid arthritis. Adv. Immune]. (1997) 64:283–350.
   PubMed Web of Science ®Google Scholar
• ••A very comprehensive review on the role of TNF-a in RA,and the development and clinical testing of cA2.
   Google Scholar
• BRYNSKOV J, NIELSON OH, AHNFELT-RONNE I et al.: Cy- tokines (inflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig. Dis. (1994) 12:290–304.
   PubMed Web of Science ®Google Scholar
• BRAEGGER CP, MACDONALD TT: Immune mechanisms in chronic inflammatory bowel disease. Ann. Allergy (1994) 72:135–141.
   PubMedGoogle Scholar
• MONTELEONE G, BIANCONE L, MARASCO R et al.: Inter-leukin-12 is expressed and actively released by Crohn's disease intestinal lamina propria mononu-clear cells. Gastroenterology (1997) 112:1169–1178.
   PubMed Web of Science ®Google Scholar
• VAN HOGEZAND RA, VERSPAGET HVV: New therapies for inflammatory bowel disease: an update on chi-meric anti-TNF-a antibodies and IL-10 therapy. Scand. Gastroenterol (1997) 223:105–107.
   Google Scholar
• •A good summary of the current status of clinical trials with IL-10 and anti-TNF-a mAb in IBD.
   Google Scholar
• WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor ne-crosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1992) 89:9784–9788.
   PubMed Web of Science ®Google Scholar
• LUDVIKSSON BR, EHRHARDT RO, FUSS IJ et al.: Mucosal and thymic disregulation. Role in human intestinal in-flammation. Immunologist (1997) 5:202–209.
   Google Scholar
• •An interesting review of two murine models of colitis and their relevance to human IBD studies.
   Google Scholar
• PODOLSKY DK: Inflammatory bowel disease. New Engl. J. Med. (1991) 325:928–937.
   PubMed Web of Science ®Google Scholar
• PODOLSKY DK: Inflammatory bowel disease. New Engl. J. Med. (1991) 325:1008–1016.
   PubMed Web of Science ®Google Scholar
• VAN DULLEMAN HM, VAN DEVENTER SJH, HOMMES DW et al.: Treatment of Crohn's disease with anti-tumor ne-crosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129–135.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, PASPARAKIS Metal: Predominant pathogenic role of tumor necrosis factor in experi-mental colitis in mice. Eur. j Immunol. (1997) 27:1743–1750.
   PubMed Web of Science ®Google Scholar
• KOJOUHAROFF G, OBERMEIER HF, MANNEL DN et al.: Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sul-phate sodium-induced colitis in mice. Clin. Exp. Immu-nol (1997) 107:353–358.
   PubMed Web of Science ®Google Scholar
• DAVIDSON NJ, FORT MM, MULLER W et al: Chronic coli-tis in 11–10-/- mice: insufficient counter regulation of a Thl response. Int. Rev Immunol (1998). (In Press.)
   Google Scholar
• RENNICK DM, FORT MM, DAVIDSON NJ: Studies with IL--/- 10 mice: an overview. J. Leuk. Biol. (1997) 61:389–396.
   Google Scholar
• BERG DJ, DAVIDSON NJ, KUHN R et al: Enterocolitis and colon cancer in interleukin-10-deficient mice are asso-ciated with aberrant cytokine production and CD4+ Till-like responses. J. Clin. Invest. (1996) 98:1010–1020.
   PubMed Web of Science ®Google Scholar
• DIELEMAN LA, PENA AS, MEUWISSEN SGM et al.: Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scand. J. Gastroenterol (1997) (Suppl. 223) 32:99-104.
   Google Scholar
• •A general summary of the role of both spontaneously occur-ring and induced animal models of colitis and their rele-vance to human IBD.
   Google Scholar
• POWRIE F, LEACH MW: Genetic and spontaneous mod-els of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regu-lation. Therap. Immunol. (1995) 2:115-123. Review of rodent colitis models and their immunological significance.
   Google Scholar
• DAVIDSON NJ, LEACH ML, FORT MM et al.: T-helper cell1-type CD4+ T cells, but not B cells, mediate colitis in in-terleukin 10-deficient mice. J. Exp. Med. (1996) 184:241–251.
   PubMed Web of Science ®Google Scholar
• MAGRAM J, CONNAUGHTON SE, WARRIER RR et al.: IL-12-deficient mice are defective in IFN-y production and type 1 cytokine responses. Immunity (1996) 4:471–481.
   PubMed Web of Science ®Google Scholar
• TRINCHIERI G: Interleukin-12: a cytokine produced byantigen-presenting cells with immunoregulatory functions in the generation of T-helper type 1 and cy-totoxic lymphocytes. Blood (1994) 84:4008–4027.
   PubMed Web of Science ®Google Scholar
• DAVIDSON NJ, HUDAK SA, LESLEY RE et al. Interleukin- 12, but not interferon-y, plays a major role in sustain-ing the chronic phase of colitis in interleukin-10-deficient mice. J. Immunol (1998) (In Press.)
   Google Scholar
• EHRHARDT RO, LUDVIKSSON BR, GRAY B et al.: Induc-tion and prevention of colonic inflammation in IL-2-deficient mice. J. Immunol. (1997) 158:566–573.
   PubMed Web of Science ®Google Scholar
• SIMPSON SJ, SHAH S, COMISKEY M et al.: T cell-mediatedpathology in two models of experimental colitis de-pends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 path-way, but is not conditional on interferon y expression by T cells. J. Exp. Med. (1998) 187:1225–1234
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, KELSALL BL et al.: Antibodies to in-terleukin-12 abrogate established experimental colitis in mice. J. Exp. Med. (1995) 182:1281–1290.
   PubMed Web of Science ®Google Scholar
• TREMBLEAU S, PENNA G, BOSI E et al: Interleukin-12 ad-ministration induces T-helper type 1 cells and acceler-ates autoimmune diabetes in NOD mice. J. Exp. Med. (1995) 181:817–821.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, WALDBURGER KE, SCHAUB RG et al: Regu-lation of the inflammatory response in animal models of multiple sclerosis. Grit. Rev. Immunol. (1997) 17:545–553.
   PubMed Web of Science ®Google Scholar
• YOKOI H, KATO K, KEZUKA T et al.: Prevention of ex-perimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur. J. Immunol (1997) 27:641–646.
   PubMed Web of Science ®Google Scholar
• MCINTYRE KW, SHUSTER DJ, GILLOOLY KM et al.: Re-duced incidence and severity of collagen-induced ar-thritis in interleukin-12-deficient mice. Eur. J. Immunol. (1996) 26:2933–2938.
   PubMed Web of Science ®Google Scholar
• MALFAIT AM, BUTLER DM, PRESKY DH et al: Blockade ofIL-12 during the induction of collagen-induced arthri-tis (CIA) markedly attenuates the severity of the arthri-tis. Clin. Exp. Immunol. (1998) 111:377–383.
   PubMed Web of Science ®Google Scholar
• MACDONALD TT: Breakdown of tolerance to the intes-tinal bacterial flora in inflammatory bowel disease (IBD). Clin. Exp. Immunol. (1995) 102:445–447.
   PubMed Web of Science ®Google Scholar
• MOLLER DR, WYSOCKA M, GREENLEE BM et al: Inhibi-tion of IL-12 production by thalidomide. J. Immunol. (1997) 159:5157–5161.
   PubMed Web of Science ®Google Scholar
• LEBEAUT A, GARAUD JJ: Clinical development of interleukin-10. Eur. Cytokine Network (1997) 8:303-304. Natalie J Davidson
   Google Scholar